© Reuters. FILE PHOTO: A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay
(Reuters) – The U.S. health regulator said on Tuesday GlaxoSmithKline (NYSE:) and Vir Biotechnology (NASDAQ:)’s drug sotrovimab was no longer authorized to treat COVID-19 in the U.S. due to an increase in the proportion of cases caused by the Omicron BA.2 sub-variant.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment